Severity of Ascites Is Associated with Increased Mortality in Patients with Cirrhosis Secondary to Biliary Atresia by Guedes, Renata R. et al.
Vol.:(0123456789) 
Digestive Diseases and Sciences 
https://doi.org/10.1007/s10620-019-06029-z
ORIGINAL ARTICLE
Severity of Ascites Is Associated with Increased Mortality in Patients 
with Cirrhosis Secondary to Biliary Atresia
Renata R. Guedes1  · Carlos O. Kieling2 · Jorge L. dos Santos3 · Carolina da Rocha4 · Fernando Schwengber5 · 
Marina R. Adami2 · Marcio F. Chedid6 · Sandra M. G. Vieira1
Received: 27 August 2019 / Accepted: 22 December 2019 
© Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract
Background Very few prior studies have investigated the presence of ascites as a prognostic factor in children with cirrhosis. 
To the best of our knowledge, there are no prior studies evaluating the relationship between severity of ascites and patient 
survival in children with biliary atresia and cirrhosis.
Aims To evaluate the association between severity of ascites and survival of children with cirrhosis and biliary atresia.
Methods All children with cirrhosis secondary to biliary atresia evaluated at our institution from 2000 to 2014 were included 
in this study. Patients were classified into four groups: NA = no ascites; A1 = grade 1 ascites; A2 = grade 2 ascites; and 
A3 = grade 3 ascites. The primary endpoint of the study was mortality within the first year after patient inclusion. Ninety-
day mortality was also evaluated. Prognostic factors related to both endpoints also were studied.
Results One-year patient survival for NA was 97.1%, versus 80.8% for A1, versus 52% for A2, versus 13.6 for A3 (p < 0.001). 
The presence of ascites increased mortality by 17 times. In the multivariate analysis, clinically detectable ascites (HR 3.14, 
95% CI 1.14–8.60, p = 0.026), lower sodium (HR 1.15, 95% CI 1.04–1.27, p = 0.006), higher bilirubin (HR 1.06, 95% CI 
1.00–1.12, p = 0.023), and higher PELD score (HR 1.05, 95% CI 1.02–1.08, p = 0.001) were all associated with decreased sur-
vival. Lower serum sodium (HR 1.20, 95% CI 1.09–1.32, p < 0.001) and higher PELD score (HR 1.03, 95% CI 1.001–1.063, 
p = 0.043) were associated with increased 90-day mortality.
Conclusions Clinically detectable ascites is associated with decreased 1-year survival of children with biliary atresia. These 
patients should be treated with caution and prioritized for liver transplantation.
Keywords Ascites · Pediatric patients · Portal hypertension · Survival · Chronic liver disease · Liver transplant
Introduction
Biliary atresia (BA) is the leading cause of chronic liver dis-
ease (CLD) and the most common indication for liver trans-
plantation (LT) in children. It is a rare disorder characterized 
by an inflammatory cholangiopathy, the etiology of which 
has not yet been clarified [1–3]. Hepatoportoenterostomy 
(HPE) is the primary therapeutic option for BA. If BA is 
left untreated, cirrhosis leads to death within 2 years [3, 4]. 
Following HPE, approximately 50% of children still develop 
long-term complications associated with cholangitis, biliary 
cirrhosis, and portal hypertension [5].
Although recent reports have demonstrated high mortality 
among infants with BA on liver waiting lists [6], few studies 
have reported the impact of decompensated cirrhosis in chil-
dren and establishing prognosis for these patients remains a 
challenge [7, 8]. In adult cirrhotic patients, ascites is often 
the first sign of CLD decompensation and is usually consid-
ered a landmark sign of cirrhosis aggravation [9–12]. Devel-
oped in the 1960s, the Child–Pugh score included presence 
of ascites as one of the variables related to worse clinical 
status [13]. In the 1980s, Malatack et al. [14] developed a 
system for assessing prognosis in cirrhotic children. In this 
scoring system, presence of ascites was also one of the vari-
ables associated with poor prognosis before LT.
Pugliese et al. [8] showed that ascites and serum sodium 
were important variables associated with waiting list mortal-
ity in a sample of more than 500 Brazilian patients. Sponta-
neous bacterial peritonitis (SBP) is a common complication 
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of ascites and one that our research team has studied. In prior 
work, we demonstrated identification of bacterial DNA in 
children with nonculture, non-neutrocytic ascites [15], and 
more recently, we reported that very poor prognosis was 
related to a first episode of SBP [16].
To the best of our knowledge, there are no prior studies 
evaluating the relationship between severity of ascites and 
survival of children with cirrhosis and BA. We hypothesize 
that the severity of ascites may be strongly associated with 
worse prognosis in pediatric patients with cirrhosis second-
ary to BA. The aim of this study was to analyze presence 
and severity of ascites as prognostic factors in survival of 
children with BA and cirrhosis.
Methods
This study was approved by the Hospital de Clinicas de 
Porto Alegre Institutional Review Board. Since the analysis 
was retrospective, informed consent waiver was obtained for 
all individual participants included in the study.
All children with cirrhosis secondary to BA, aged 
12 years or younger, seen at the Pediatric Gastroenterology 
and Hepatology Unit at the Hospital de Clinicas de Porto 
Alegre from March 2000 to July 2014 were included in this 
historical cohort. Patients had previous or no Kasai surgery 
and were studied retrospectively. For patients who never 
developed ascites, inclusion was performed at the time of 
diagnosis of cirrhosis. For patients who developed ascites, 
the inclusion was accomplished on its first episode. Accord-
ingly, for each patient, the severity of ascites was recorded 
as it was on its first episode.
We excluded patients with other previous abdominal sur-
gery, gastrointestinal bleeding due to portal hypertension, 
SBP, or sepsis or other systemic infection within a four-week 
span before ascites diagnosis.
After enrollment, patients were classified into four 
groups: (1) NA = no ascites; (2) A1 = grade 1 ascites; (3) 
A2 = grade 2 ascites; and (4) A3 = grade 3 ascites. Ascites 
was diagnosed by abdominal ultrasound and classified 
according to the international criteria [17]. Most of those 
patients (53/72 with and 13/34 without ascites) were on the 
waiting transplant list.
The primary outcome was mortality occurring at any time 
within the first year after patient inclusion. The secondary 
outcome was mortality occurring within the first 90 days. 
Prognostic factors related to both outcomes were analyzed.
Since mortality was the event of interest, patients who 
underwent LT were removed from the analysis (censored 
statistically). No investigations or interventions were per-
formed for the purpose of the study, and no patients were 
included more than once.
All patients underwent routine diagnostic assessment 
according to a routine diagnostic protocol which included 
complete blood count, coagulation tests (platelets, prothrom-
bin time estimated by the international normalized ratio 
[INR]), liver and renal biochemical tests (total and conju-
gated serum bilirubin, aspartate aminotransferase, alanine 
aminotransferase, alkaline phosphatase, gamma glutamyl-
transferase, serum albumin, creatinine, urea), and blood cul-
tures. The SBP treatment protocol was in accordance with 
international guidelines [17].
Cumulative probability of survival by groups was calcu-
lated using the Kaplan–Meier method, and curves were com-
pared using the log-rank test. A p value of less than 0.05 was 
considered significant. Univariate analysis was performed 
to identify variables related to decreased survival for both 
time endpoints using the Cox regression method. Variables 
analyzed included: age at inclusion, Pediatric End-Stage 
Liver Disease (PELD) score [18], nutritional status as deter-
mined by height/age z-score, prothrombin time as assessed 
by INR, total bilirubin, serum albumin, and serum sodium. 
For statistical analysis, age was categorized as 0–1 years 
versus ≥ 1 year. Malnutrition was defined as a height/age 
z-score < − 2. The distribution of continuous numeric vari-
ables was assessed using the Shapiro–Wilk test. Continuous 
variables with normal distribution were expressed as mean 
and standard deviation and compared using the T-test and/
or ANOVA as appropriate. Continuous variables without 
normal distribution were expressed as median and interquar-
tile interval (percentiles 25 and 75) and compared using the 
Kruskal–Wallis and Mann–Whitney tests.
Categorical variables were presented as percentages and 
were compared using the Chi-square test. A multivariate 
analysis was performed to identify independent predictors 
of survival. Variables with a p value equal to or lower than 
0.05 in univariate analysis were subsequently included in 
this multivariate proportional hazards Cox analysis. Data 
analysis was conducted using the Statistical Package for 
Social Sciences, version 18.0 (SPSS Inc. Released 2009. 
PASW Statistics for Windows, Version 18.0. Chicago-USA).
Results
One hundred and twenty consecutive children with BA were 
reviewed. Fourteen of these were excluded due to missing 
data. Thus, a total of 106 patients were included in this study. 
Eighty-nine of those 106 patients had undergone a prior 
HPE. Thirty-nine out of the 89 patients had biliary drainage 
following HPE. Sixteen of those developed decompensations 
with ascites. The remaining 50 patients failed the Kasai pro-
cedure. Forty-one of those were enlisted to liver transplan-
tation. From these, 29 were under 1 year old and required 
early liver transplantation. (We defined early transplantation 
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as the procedure performed during the first year of patient’s 
life and HPE failure as total bilirubin > 2 mg/dL post-HPE.)
Demographic data and clinical characteristics of the study 
population are summarized in Table 1. Most children were 
under 1 year old when included in the study. Only 31 of 106 
were over 1 year old. The oldest patient was 7 years old.
The prevalence of ascites was 68% (72 patients). Thirty-
four of the whole sample of 106 patients (32.1%) had no 
ascites. Of the 72 patients with ascites, 26.4% had mild 
ascites, 28.3% had moderate ascites, and 13.2% had severe 
ascites (Table 1). Thirteen of the 34 patients without ascites 
and 53 of the 72 patients with ascites were on the waiting 
transplant list.
Table 2 shows patient data by presence of ascites. Patients 
with ascites were more commonly younger than 1 year, had 
worse nutritional status, more severe hepatic synthetic dys-
function, lower serum sodium, and higher PELD scores.
During the first year of observation, 31 of the 106 patients 
(26.4%) underwent LT. Figure 1a illustrates transplant-free 
1-year patient survival of the entire cohort (patients who 
underwent LT during the first year of observation were cen-
sored). Twenty-seven of the 75 patients who did not have LT 
died during the first year of follow-up (mortality rate = 36%).
Figure 1b shows a survival comparison according to 
presence of ascites. One-year patient survival for patients 
without ascites was 97.1% versus 56.9% for patients with 
ascites (p = 0.001).
Figure 1c shows transplant-free survival for the four 
patient groups (NA, A1, A2 and A3). For the NA group, 
1-year survival was 97.1%, versus 80.8% for the A1 group, 
versus 52% for the A2 group, versus 13.6 for the A3 group 
(p < 0.001).
There was no difference between survival in NA and A1 
groups (p = 0.079) or between A2 and A3 groups. Thus, 
patients without ascites (NA) were combined into one group 
with patients with mild ascites (A1) and A2 patients were 
also combined with A3 patients into a single group. One-
year survival in the NA + A1 group was compared to that in 
the A2 + A3 group (Fig. 1d). One-year patient survival in 
the NA + A1 group was 89.9% versus 39.3% in the A2 + A3 
group (p < 0.001).
Table 3 shows variables related to decreased survival 
according to Cox proportional hazards regression. Mortal-
ity of patients was increased by 17 times by the presence of 
ascites (HR 17.32, 95% CI 2.34–128.02, p = 0.005). Clini-
cally, detectable ascites (A2 and A3 groups) increased mor-
tality by 8 times (HR 8.04, 95% CI 3.22–20.09, p < 0.001). 
Lower albumin was associated with a fourfold increase in 
1-year mortality (HR 4.19, 95% CI 2.2–8.29, p < 0.001). Age 
younger than 1 year was associated with a threefold decrease 
in 1-year survival (HR 3.02, 95% CI 1.04–8.73, p = 0.042). 
Table 1  Demographic data for 106 children with biliary atresia 
(n = 106)
Patients, n 106




 No (NA) 34 (32.1%)
 Grade 1 (A1) 28 (26.4%)
 Grade 2 (A2) 30 (28.3%)
 Grade 3 (A3) 14 (13.2%)
Kasai procedure, n (%) 89 (84.0%)
Age at Kasai procedure (days), median (p25–p75) 67 (56–84)
Patients who underwent liver transplantation during first 
year of follow-up, n (%)
31 (29%)
Type of transplant, n (%)
 Living donor liver transplant 4 (13%)
 Orthotopic liver transplant 27 (87%)
Table 2  Patient data by presence of ascites








Age < 1 year, n (%) 57 (79.2%) 18 (52.9%) 75 (70.8%) 0.011
Female gender, n (%) 43 (59.7%) 19 (55.9%) 62 (58.5%) 0.833
Kasai procedure, n (%) 59 (81.9%) 30 (88.2%) 89 (84%) 0.573
Total bilirubin ≤ 2 mg/dL post-Kasai, n (%) 16 (27.1%) 23 (76.7%) 39 (43.8%) < 0.001
Height for age z-score, median [IQR 25–75] − 2.08 [− 2.90 to − 1.32] − 0.93 [− 1.94 to − 0.33] − 1.87 [− 2.68 to − 0.88] < 0.001
Albumin (g/dL), median [IQR 25–75] 2.8 [2.3 to 3.18] 3.6 [3.3 to 4.2] 3.5 [2.5 to 3.1] < 0.001
Total bilirubin (mg/dL), median [IQR 25–75] 13.4 [6.5 to 17.5] 1.9 [0.7 to 9.5] 10.4 [2.1 to 16.4] < 0.001
INR, median [IQR 25–75] 1.36 [1.19 to 1.65] 1.10 [1.02 to 1.27] 1.30 [1.10 to 1.55] < 0.001
Serum sodium (mEq/L), median [IQR 25–75] 135 [132 –137.8] 138 [134.8 to 138.3] 136 [133 to 138] 0.018
PELD score, median [IQR 25–75] 18 [13 to 25] 3.5 [− 7.3 to 11.3] 15 [5 to 22] < 0.001
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The other variables related to the decreased 1-year survival 
were elevated serum bilirubin, elevated INR, and higher 
PELD. Lower serum sodium was also related to increased 
mortality (Table 3).
Albumin, bilirubin, INR, age, and nutrition status are all 
part of the PELD score. Therefore, combining any of these 
factors with the PELD score in the same multivariate model 
would create a potential for collinearity and so two differ-
ent multivariate models were constructed. In the first (not 
using PELD score, but using age, nutrition status, bilirubin, 
INR, and albumin), the three variables independently related 
to increased mortality were moderate and severe ascites 
(groups A2 and A3) (HR 3.14, 95% CI 1.14–8.60, p = 0.026), 
low sodium (HR 1.15, 95% CI 1.04–1.27, p = 0.006), and 
Fig. 1  a One-year patient survival of the 106 patients (patients 
who underwent LT were censored). b One-year patient survival, 
by presence of ascites (patients who underwent LT were censored) 
(p < 0.001). c One-year patient survival for the four patient groups 
(NA, A1, A2, and A3) (patients who underwent LT were censored) 
(p < 0.001). d Comparison of 1-year transplant-free patient survival 
in two groups: patients without ascites (NA) or with grade 1 ascites 
(A1) versus patients with grade 2 or 3 ascites (A2 and A3) (p < 0.001)
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elevated bilirubin (HR 1.06, 95% CI 1.00–1.12, p = 0.023) 
(Table 4).
In the multivariate model that included the PELD score, 
presence of moderate and severe ascites (groups A2 and A3) 
was also the strongest predictive variable (HR 3.24, 95% 
CI 1.17–8.96, p = 0.023) (Table 5). Lower serum sodium 
was associated with a higher mortality risk (HR 1.13, 95% 
CI 1.03–1.25, p = 0.009). Interestingly, the PELD score was 
only associated with a marginal increase in mortality risk 
(HR 1.05, 95% CI 1.02–1.08, p = 0.001).
The same statistical analyses were employed to evalu-
ate 90-day survival. Patients with and without ascites had 
statistically different survival rates. Patients with ascites 
(A1 + A2 + A3) had lower 90-day survival (Fig. 2a). The 
90-day survival for patients with clinically detectable ascites 
was significantly lower than survival among patients without 
ascites (Fig. 2b, c).
Univariate analyses revealed that presence of ascites, 
presence of clinically detectable ascites (A2 and A3 groups), 
lower albumin, increased serum bilirubin, increased INR, 
higher PELD, and also decreased serum sodium also were 
all related to increased mortality (Table 6). The multivariate 
model that did not include the PELD score revealed that only 
lower serum sodium was associated with increased mortal-
ity (HR 1.21, 95% CI 1.10–1.33, p < 0.001) (Table 7). The 
multivariate model that did include PELD score revealed 
that both lower serum sodium (HR 1.20, 95% CI 1.09–1.32, 
p < 0.001) and PELD score were associated with increased 
mortality (HR 1.03, 95% CI 1.001–1.063, p = 0.043) 
(Table 8).
Discussion
Most children with BA will eventually develop CLD [4, 
5]. In the first years of life, progression to cirrhosis occurs 
in patients with late diagnosis of BA or failure after HPE. 
These patients develop severe hepatic synthetic dysfunction 
during a period of immature hepatic function and vulner-
ability to nutritional compromise [19–21]. Children with 
ascites, and especially infants, are prone to organ dysfunc-
tion [8]. It has been proposed that systemic inflammation 
plays an important role in the course of ascites and is associ-
ated with decompensation in adult patients [9]. The response 
to inflammation is individual, and certain aspects are age 
related.
The impact of ascites on morbidity and mortality is well 
known in adult cirrhotic patients [11, 12, 17], in whom 
1-year and 2-year mortality are nearly 40% and 50%, respec-
tively [17]. Only a very few prior studies have investigated 
presence of ascites as a prognostic factor in children with 
cirrhosis [8, 22, 23]. Pugliese et al. [8] studied 522 pedi-
atric patients with end-stage liver disease listed for LT due 
to several etiologies. They detected that presence of ascites 
was independently associated with a lower survival rate at 
90 days (58.8% vs. 83.8%). Specifically with children with 
BA, Jiang et al. analyzed a total of 133 patients who had 
undergone Kasai procedures. They detected that presence 
of ascites was one of the variables related to poor prognosis 
[22]. They also proposed a scoring system to predict which 
Table 3  Univariate analysis of variables related to 1-year patient sur-
vival, by Cox proportional hazards regression
INR international normalized ratio, PELD score Pediatric End-Stage 
Liver Disease score, HR hazards ratio
a For these variables, lower values were associated with worse out-
comes
Variable HR 95% CI p value
Male gender 1.04 0.48–2.25 0.913
Age < 1 year 3.02 1.04–8.73 0.042
Height for age z-scorea 1.27 0.98–1.64 0.067
Presence of ascites 17.32 2.34–128.02 0.005
Presence of clinically detect-
able ascites (grades 2 and 3)
8.04 3.22–20.09 < 0.001
Total bilirubin 1.10 1.06–1.14 < 0.001
INR 1.30 1.17–1.46 < 0.001
Albumina 4.19 2.12–8.29 < 0.001
Serum  sodiuma 1.22 1.13–1.31 < 0.001
PELD score 1.09 1.06–1.11 < 0.001
Table 4  Variables related to 1-year patient survival, by multivariate 
Cox proportional hazards regression (model not including PELD)
INR international normalized ratio, PELD score Pediatric End-Stage 
Liver Disease score, HR hazards ratio
Variable HR 95% CI p value
Ascites grade (NA + A1 groups 
versus A2 + A3 groups)
3.14 1.14–8.60 0.026
Albumin 1.98 0.86–4.52 0.105
Total bilirubin 1.06 1.00–1.12 0.023
INR 1.03 0.87–1.21 0.742
Serum sodium 1.15 1.04–1.27 0.006
Age < 1 year 1.40 0.46–4.24 0.552
Table 5  Variables related to 1-year patient survival, by multivariate 
Cox proportional hazards regression (Model including PELD)
PELD score Pediatric End-Stage Liver Disease score, HR hazards 
ratio
Variable HR 95% CI p value
Ascites grade (NA + A1 groups 
versus A2 + A3 groups)
3.24 1.17–8.96 0.023
Serum sodium 1.13 1.03–1.25 0.009
PELD score 1.05 1.02–1.08 0.001
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patients should be considered for LT. However, none of these 
studies stratified the degree of ascites.
To the best of our knowledge, this is the first study report-
ing that moderate and severe ascites is related to increased 
mortality in children with cirrhosis. Ascites was the main 
independent adverse prognostic factor in a cohort of 106 
patients with end-stage liver disease secondary to BA. Pres-
ence of grades 2 and 3 ascites was related to a threefold 
increase in 1-year mortality. Although no prior studies have 
evaluated the relationship between degree of ascites and 
mortality in children, Zipprich et al. did study a large cohort 
(n = 443) of adult cirrhotic patients stratified by degree of 
ascites. They observed that even patients with subclinical 
ascites (grade 1) had lower survival than patients without 
ascites [12]. In contrast to these findings, our study did not 
detect mild ascites as an adverse prognostic factor. This is 
Fig. 2  a 90-day patient survival, by presence of ascites (p = 0.016). b 
90-day transplant-free patient survival for all four patient groups (NA, 
A1, A2 and A3) (p < 0.001). c Comparison of 90-day transplant-free 
patient survival in two groups: patients without ascites (NA) or with 
grade 1 ascites (A1) versus patients with grade 2 or 3 ascites (A2 and 
A3) (p < 0.001)
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likely to be due to the relatively small sample size of our 
study.
Lower sodium and increased bilirubin were indepen-
dently related to decreased 1-year and 90-day mortality. 
Lower sodium was associated with a 15% increase in 
mortality. PELD score was also associated with a mild 
increase in 1-year mortality. Pugliese et al. also identi-
fied ascites, total bilirubin level, and low serum sodium 
level as independently related to 90-day mortality. They 
also found that low serum sodium levels were related to a 
minimal increase in mortality [8].
Although age younger than 1 year was identified as an 
adverse prognostic factor in the univariate analysis, asso-
ciated with a threefold increase in 1-year mortality, the 
multivariate analysis failed to confirm this finding. The 
younger the patient, the higher the inflammatory response, 
the more impaired the immunological tolerance, or both 
[21].
Our study revealed that three-month mortality was only 
increased by lower sodium and higher PELD scores. Inter-
estingly, the results of the present study revealed that the 
PELD score was only associated with a very small increase 
in 1-year mortality (5%) and an even lower increase in 
90-day mortality. In contrast, presence of clinically detect-
able ascites was associated with an increase in 1-year mor-
tality exceeding 300%. This association was also detected in 
the univariate analysis, as an eightfold increase in mortality. 
However, this association was not confirmed in the multi-
variate analysis of 90-day survival. There may be a chance 
that our study was underpowered to detect a difference.
A recent study evaluating adult patients with cirrhosis 
detected that ascites had better prognostic accuracy than 
the MELD score alone in patients with low MELD scores 
[24]. However, presence of ascites is not part of the MELD 
score and so the current system for allocation of livers from 
deceased donors to pediatric patients based on the PELD 
score does not consider the presence of ascites.
This study has some limitations. The first is its retrospec-
tive, single-center nature. Nevertheless, the study was based 
on a database that is populated prospectively. While the size 
of the sample is not large, it is composed exclusively of BA 
patients. These aspects may strengthen the homogeneity 
of the population and the selection criteria, increasing the 
validity of the study.
In conclusion, our study revealed that clinically detect-
able ascites was independently associated with a threefold 
increase in 1-year mortality of cirrhotic patients with BA. 
Moreover, moderate and severe ascites were the strong-
est adverse prognostic factors with much higher odds for 
mortality than the PELD score and the few other adverse 
variables. Conversely, this association was not confirmed for 
90-day mortality, likely due to our study’s small sample size. 
The PELD score was associated with a minimal increase 
in both 1-year and 90-day mortality of children with BA. 
Larger studies are warranted to investigate whether ascites 
is related to increased 90-day mortality of children with 
BA. Therefore, children with BA and clinically detectable 
ascites should be listed for LT. Living donor LT should be 
strongly considered as a suitable alternative for this patient 
population.
Table 6  Univariate analysis of variables related to 90-day patient sur-
vival, by Cox proportional hazards regression
INR international normalized ratio, PELD score Pediatric End-Stage 
Liver Disease score, HR hazards ratio
a For these variables, lower values were associated with worse out-
comes
Variable HR 95% CI p value
Male gender 1.26 0.74–2.10 0.392
Age < 1 year 7.18 0.95–54.35 0.056
Height for age z-scorea 1.25 0.45–3.43 0.668
Presence of ascites 8.10 1.10–61.30 0.043
Presence of clinically detectable 
ascites (grades 2 and 3)
7.90 2.20–27.80 0.001
Total bilirubin 1.10 1.05–1.16 < 0.001
INR 1.28 1.14–1.44 < 0.001
Albumina 3.74 1.53–9.17 0.004
Serum  sodiuma 1.25 1.15–1.36 < 0.001
PELD score 1.07 1.04–1.10 < 0.001
Table 7  Variables related to 90-day patient survival, by multivariate 
Cox proportional hazards regression (Model not including PELD)
INR international normalized ratio, PELD score Pediatric End-Stage 
Liver Disease score, HR hazards ratio
Variable HR 95% CI p value
Ascites grade (NA + A1 groups 
versus A2 + A3 groups)
2.37 0.57–9.93 0.238
Albumin 1.69 0.55–5.24 0.363
Total bilirubin 1.06 0.98–1.14 0.128
INR 0.99 0.83–1.20 0.967
Serum sodium 1.21 1.10–1.33 < 0.001
Age < 1 year 2.78 0.35–22.30 0.336
Table 8  Variables related to 90-day patient survival, by multivariate 
Cox proportional hazards regression (model including PELD)
PELD score Pediatric End-Stage Liver Disease score, HR hazards 
ratio
Variable HR 95% CI p value
Ascites grade (NA + A1 groups 
versus A2 + A3 groups)
3.18 0.79–12.92 0.105
Serum sodium 1.20 1.09–1.32 < 0.001
PELD score 1.03 1.001–1.063 0.043
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